• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.

作者信息

Malik Rhea, Xiang David H, Riew Grant J, Sanchez-Melendez Stephanie, Afvari Shawn, LeBoeuf Nicole R, Nambudiri Vinod E

机构信息

Harvard Medical School, Boston, Massachusetts; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.

Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Ponce Health Sciences University, School of Medicine, Ponce, Puerto Rico.

出版信息

J Am Acad Dermatol. 2024 Oct;91(4):753-755. doi: 10.1016/j.jaad.2024.06.037. Epub 2024 Jun 21.

DOI:10.1016/j.jaad.2024.06.037
PMID:38909660
Abstract
摘要

相似文献

1
Characterization of adverse cutaneous effects in the setting of enfortumab vedotin for metastatic urothelial carcinoma: A retrospective review.恩杂鲁胺治疗转移性尿路上皮癌时皮肤不良反应的特征：一项回顾性研究。
J Am Acad Dermatol. 2024 Oct;91(4):753-755. doi: 10.1016/j.jaad.2024.06.037. Epub 2024 Jun 21.
2
Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.尿路上皮癌患者中恩杂鲁胺相关皮肤毒性的临床病理特征
J Am Acad Dermatol. 2021 Dec;85(6):1610-1611. doi: 10.1016/j.jaad.2020.11.067. Epub 2020 Dec 7.
3
Efficacy and safety of enfortumab vedotin in older patients with metastatic urothelial carcinoma: A multicenter retrospective study.恩杂鲁胺治疗老年转移性尿路上皮癌患者的疗效和安全性：一项多中心回顾性研究。
J Geriatr Oncol. 2025 Mar;16(2):102183. doi: 10.1016/j.jgo.2024.102183. Epub 2025 Jan 9.
4
Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.中国经治局部晚期或转移性尿路上皮癌患者的恩福妥昔单抗Vedotin Ⅱ期临床试验。
Cancer Med. 2024 Nov;13(21):e70368. doi: 10.1002/cam4.70368.
5
Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.与恩杂鲁胺治疗转移性尿路上皮癌相关的皮肤毒性。
Dermatol Online J. 2019 Feb 15;25(2):13030/qt4j44w7w6.
6
Enfortumab vedotin-induced widespread vesiculobullous eruption mimicking disseminated herpetic infection in a patient with metastatic urothelial carcinoma.恩杂鲁胺诱导转移性尿路上皮癌患者出现广泛的水疱大疱性皮疹，酷似播散性疱疹感染。
Dermatol Online J. 2024 Dec 15;30(6). doi: 10.5070/D330664684.
7
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺与帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):280-281. doi: 10.1016/j.eururo.2024.03.029. Epub 2024 Apr 9.
8
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):282-283. doi: 10.1016/j.eururo.2024.03.032. Epub 2024 Apr 16.
9
Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.关于：恩杂鲁胺和帕博利珠单抗用于未经治疗的晚期尿路上皮癌
Eur Urol. 2024 Sep;86(3):283. doi: 10.1016/j.eururo.2024.05.001. Epub 2024 May 13.
10
Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?恩福妥单抗和帕博利珠单抗联合治疗在尿路上皮癌中的相关变革：还有什么遗留问题？
Med. 2024 Jun 14;5(6):490-492. doi: 10.1016/j.medj.2024.04.006.

引用本文的文献

1
One Man's Meat Is Another Man's Poison: High Incidence of Severe Cutaneous Drug Reactions Induced by Enfortumab Vedotin.一人之佳肴，他人之毒药：恩扎妥昔单抗所致严重皮肤药物不良反应的高发生率
Eur Urol Open Sci. 2025 Aug 15;80:5-13. doi: 10.1016/j.euros.2025.08.001. eCollection 2025 Oct.
2
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers.泌尿生殖系统癌症全身治疗中皮肤毒性的诊断与管理
Cancers (Basel). 2025 Jan 14;17(2):251. doi: 10.3390/cancers17020251.